UA56132C2
(en)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
|
US6231859B1
(en)
|
1996-12-02 |
2001-05-15 |
Aquila Biopharmaceuticals, Inc. |
Saponin adjuvant compositions
|
WO1998024319A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Aquila Biopharmaceuticals, Inc. |
Novel saponin compositions and uses thereof
|
WO1999010008A1
(en)
*
|
1997-08-29 |
1999-03-04 |
Aquila Biopharmaceuticals, Inc. |
Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
|
GB9817052D0
(en)
*
|
1998-08-05 |
1998-09-30 |
Smithkline Beecham Biolog |
Vaccine
|
EP1104306B1
(en)
|
1998-08-10 |
2006-01-11 |
Antigenics Inc. |
Compositions of cpg and saponin adjuvants and methods of use thereof
|
AUPP807399A0
(en)
*
|
1999-01-08 |
1999-02-04 |
Csl Limited |
Improved immunogenic lhrh composition and methods relating thereto
|
DK2204186T3
(en)
|
1999-02-17 |
2016-07-18 |
Csl Ltd |
Immunogenic complexes, and related methods
|
IL145982A0
(en)
|
1999-04-19 |
2002-07-25 |
Smithkline Beecham Biolog |
Vaccines
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
US8017590B1
(en)
|
1999-10-22 |
2011-09-13 |
Sanofi Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
DE60039715D1
(en)
*
|
1999-11-19 |
2008-09-11 |
Csl Ltd |
HCV VACCINE COMPOSITIONS
|
EP1282702B1
(en)
|
2000-05-10 |
2006-11-29 |
Sanofi Pasteur Limited |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
AUPR011700A0
(en)
*
|
2000-09-14 |
2000-10-05 |
Austin Research Institute, The |
Composition comprising immunogenic virus sized particles (VSP)
|
PL211151B1
(en)
|
2000-10-18 |
2012-04-30 |
Glaxosmithkline Biolog Sa |
Vaccines
|
AU2002254901A1
(en)
|
2001-02-23 |
2002-10-03 |
Smithkline Beecham Biologicals S.A. |
Influenza vaccine formulations for intradermal delivery
|
US7713942B2
(en)
*
|
2001-04-04 |
2010-05-11 |
Nordic Vaccine Technology A/S |
Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AUPR446801A0
(en)
|
2001-04-18 |
2001-05-17 |
University Of Queensland, The |
Novel compositions and uses therefor
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
SE0202110D0
(en)
*
|
2002-07-05 |
2002-07-05 |
Isconova Ab |
Iscom preparation and use thereof
|
JP4697706B2
(en)
|
2002-10-11 |
2011-06-08 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
Polypeptide-vaccine for broad protection against highly virulent meningococcal strains
|
WO2004037189A2
(en)
|
2002-10-23 |
2004-05-06 |
Glaxosmithkline Biologicals S.A. |
Methods for vaccinating against malaria
|
CA3042073C
(en)
|
2003-01-30 |
2022-09-13 |
Novartis Vaccines And Diagnostics S.R.L. |
Injectable vaccines against multiple meningococcal serogroups
|
SE0300795D0
(en)
|
2003-03-24 |
2003-03-24 |
Isconova Ab |
Composition comprising iscom particles and live micro-organisms
|
JP2007537975A
(en)
|
2003-06-10 |
2007-12-27 |
ザ ユニバーシティー オブ メルボルン |
Immunomodulatory compositions, methods for their use and methods for their manufacture
|
SE0301998D0
(en)
*
|
2003-07-07 |
2003-07-07 |
Isconova Ab |
Quil A fraction with low toxicity and use thereof
|
WO2005032582A2
(en)
|
2003-07-31 |
2005-04-14 |
Chiron Corporation |
Immunogenic compositions for streptococcus pyogenes
|
WO2005033278A2
(en)
*
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
JP4738339B2
(en)
|
2003-10-02 |
2011-08-03 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
Liquid vaccine for multiple meningococcal serogroups
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
EP1682159A4
(en)
|
2003-10-16 |
2010-07-21 |
Stephen John Ralph |
Immunomodulating compositions and uses therefor
|
GB0402131D0
(en)
|
2004-01-30 |
2004-03-03 |
Isis Innovation |
Delivery method
|
EP1722815A1
(en)
|
2004-03-09 |
2006-11-22 |
Chiron Corporation |
Influenza virus vaccines
|
EP1740217B1
(en)
|
2004-04-30 |
2011-06-15 |
Novartis Vaccines and Diagnostics S.r.l. |
Meningococcal conjugate vaccination
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
JP4896021B2
(en)
|
2004-05-21 |
2012-03-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
Alphavirus vector for respiratory pathogen vaccine
|
ATE491467T1
(en)
|
2004-05-28 |
2011-01-15 |
Glaxosmithkline Biolog Sa |
VACCINE COMPOSITIONS CONTAINING VIROSOMES AND A SAPONIN ADJUVANT
|
US20090317420A1
(en)
|
2004-07-29 |
2009-12-24 |
Chiron Corporation |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
CA2592627C
(en)
|
2005-01-20 |
2014-02-25 |
Isconova Ab |
Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
NZ561042A
(en)
|
2005-02-18 |
2011-03-31 |
Novartis Vaccines & Diagnostic |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CN101273055B
(en)
|
2005-04-29 |
2016-03-16 |
葛兰素史密丝克莱恩生物有限公司 |
For preventing or treat the novel method of m tuberculosis infection
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
EP1764369A1
(en)
|
2005-09-16 |
2007-03-21 |
Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH |
Vaccines comprising truncated HBC core protein plus saponin-based adjuvant
|
DK179025B1
(en)
|
2005-09-16 |
2017-08-28 |
Intervet Int Bv |
fish vaccine
|
CN101355960A
(en)
|
2005-10-18 |
2009-01-28 |
诺华疫苗和诊断公司 |
Mucosal and systemic immunizations with alphavirus replicon particles
|
EP1779866A1
(en)
|
2005-11-01 |
2007-05-02 |
Intervet International BV |
Prime-boost vaccine for the protection of equines against viral infection
|
US10842867B2
(en)
|
2005-11-04 |
2020-11-24 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
BRPI0707300B8
(en)
|
2006-01-27 |
2021-05-25 |
Novartis Ag |
split influenza virion vaccine or purified surface antigen and method for preparing an immunogenic composition
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
AU2007231027B2
(en)
|
2006-03-24 |
2013-10-03 |
Novartis Influenza Vaccines Marburg Gmbh |
Storage of influenza vaccines without refrigeration
|
CA2647942A1
(en)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
EP2035035A2
(en)
|
2006-06-09 |
2009-03-18 |
Novartis AG |
Immunogenic compositions for streptococcus agalactiae
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
MX2009002408A
(en)
|
2006-09-11 |
2009-03-20 |
Novartis Ag |
Making influenza virus vaccines without using eggs.
|
WO2008031878A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH |
A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
|
EP1902727A1
(en)
*
|
2006-09-22 |
2008-03-26 |
Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH |
Vaccines comprising truncated HBC core protein plus saponin-based adjuvants
|
AU2007354917B2
(en)
|
2006-09-26 |
2013-06-06 |
Access To Advanced Health Institute |
Vaccine composition containing synthetic adjuvant
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
EP2094278B1
(en)
*
|
2006-11-20 |
2017-04-05 |
Duecom |
Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
|
EP2121011B1
(en)
|
2006-12-06 |
2014-05-21 |
Novartis AG |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
LT2137210T
(en)
|
2007-03-02 |
2016-12-27 |
Glaxosmithkline Biologicals Sa |
Novel method and compositions
|
CA2679720A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Merck & Co., Inc. |
Papillomavirus vaccine compositions
|
CA2688284A1
(en)
|
2007-05-25 |
2008-12-04 |
Novartis Ag |
Streptococcus pneumoniae pilus antigens
|
PT2185191E
(en)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
KR20100068390A
(en)
|
2007-08-13 |
2010-06-23 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
Vaccines
|
MX2010002773A
(en)
|
2007-09-12 |
2010-03-31 |
Novartis Ag |
Gas57 mutant antigens and gas57 antibodies.
|
EP2062594A1
(en)
|
2007-11-21 |
2009-05-27 |
Wyeth Farma, S.A. |
Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CN104292312A
(en)
|
2007-12-21 |
2015-01-21 |
诺华股份有限公司 |
Mutant forms of streptolysin o
|
SI2222710T1
(en)
|
2007-12-24 |
2016-11-30 |
Id Biomedical Corporation Of Quebec |
Recombinant rsv antigens
|
EP2231257A4
(en)
*
|
2007-12-24 |
2013-11-06 |
Univ Queensland |
Coating method
|
CA2749347C
(en)
*
|
2008-02-07 |
2018-03-27 |
The University Of Queensland |
Patch production
|
US9579372B2
(en)
|
2008-02-21 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Meningococcal fHBP polypeptides
|
CA2718430A1
(en)
|
2008-03-18 |
2009-09-24 |
Novartis Ag |
Improvements in preparation of influenza virus vaccine antigens
|
WO2009143524A2
(en)
|
2008-05-23 |
2009-11-26 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
CA2760680A1
(en)
*
|
2008-05-23 |
2009-11-26 |
The University Of Queensland |
Analyte detection by microneedle patch with analyte selective reagents
|
CN102223876A
(en)
|
2008-09-26 |
2011-10-19 |
纳米生物公司 |
Nanoemulsion therapeutic compositions and methods of using the same
|
AU2009325950B2
(en)
|
2008-12-09 |
2013-03-07 |
Pfizer Vaccines Llc |
IgE CH3 peptide vaccine
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
US9265821B2
(en)
|
2009-02-17 |
2016-02-23 |
Glaxosmithkline Biologicals Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
JP2012519482A
(en)
|
2009-03-06 |
2012-08-30 |
ノバルティス アーゲー |
Chlamydia antigen
|
DK2510947T3
(en)
|
2009-04-14 |
2016-03-21 |
Glaxosmithkline Biolog Sa |
Compositions for Immunization against Staphylococcus aureus.
|
WO2010125480A1
(en)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
MX2011012347A
(en)
*
|
2009-05-22 |
2012-02-21 |
Genocea Biosciences Inc |
Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response.
|
CA2764374C
(en)
|
2009-06-05 |
2019-11-19 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants
|
CN102802665B
(en)
|
2009-06-15 |
2015-11-25 |
新加坡国立大学 |
Influenza vaccines, compositions and using method
|
EP2442827B1
(en)
|
2009-06-16 |
2016-01-06 |
The Regents of the University of Michigan |
Nanoemulsion vaccines
|
MX2012000036A
(en)
|
2009-06-24 |
2012-02-28 |
Glaxosmithkline Biolog Sa |
Vaccine.
|
WO2010149745A1
(en)
|
2009-06-24 |
2010-12-29 |
Glaxosmithkline Biologicals S.A. |
Recombinant rsv antigens
|
EP2451833B1
(en)
|
2009-07-07 |
2018-01-17 |
GlaxoSmithKline Biologicals SA |
Conserved escherichia coli immunogens
|
ES2563730T3
(en)
|
2009-07-15 |
2016-03-16 |
Glaxosmithkline Biologicals S.A. |
RSV F protein compositions and manufacturing processes thereof
|
DK2464658T3
(en)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
RU2518291C2
(en)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Antigen tau-peptides and their application
|
US20110076300A1
(en)
|
2009-08-27 |
2011-03-31 |
Mariagrazia Pizza |
Hybrid Polypeptides Including Meningococcal fHBP Sequences
|
US20110110980A1
(en)
|
2009-09-02 |
2011-05-12 |
Wyeth Llc |
Heterlogous prime-boost immunization regimen
|
CA2771770A1
(en)
|
2009-09-03 |
2011-03-10 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
WO2011030218A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
MY157607A
(en)
*
|
2009-09-10 |
2016-06-30 |
Merial Inc |
New vaccine formulations comprising saponin-containing adjuvants
|
DK2477652T3
(en)
|
2009-09-16 |
2015-07-20 |
Vaxart Inc |
Immunization strategy for the prevention of infection H1Ni
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
EP2483390A2
(en)
|
2009-09-30 |
2012-08-08 |
Novartis AG |
Expression of meningococcal fhbp polypeptides
|
AU2010352695B2
(en)
|
2009-09-30 |
2014-08-21 |
Glaxosmithkline Biologicals S.A. |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
CA2779816A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
CA2785585A1
(en)
|
2009-12-22 |
2011-06-30 |
Celldex Therapeutics, Inc. |
Vaccine compositions
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
CA2796314A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Benzonapthyridine compositions and uses thereof
|
JP2013532008A
(en)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
Interactive hybrid asynchronous computer game infrastructure
|
EP2576613A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
CA2800774A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
US9943673B2
(en)
|
2010-07-14 |
2018-04-17 |
Vaxxas Pty Limited |
Patch applying apparatus
|
EP3272359A1
(en)
|
2010-07-23 |
2018-01-24 |
Novavax AB |
Influenza vaccine
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
CA2808556A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
JP2013545453A
(en)
|
2010-11-01 |
2013-12-26 |
ユニバーシティ・オブ・テクノロジー、シドニー |
Immunomodulators and their use
|
WO2012074881A2
(en)
*
|
2010-11-24 |
2012-06-07 |
Genocea Biosciences, Inc. |
Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
EP2655389A2
(en)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Compounds
|
DK2667892T3
(en)
|
2011-01-26 |
2019-05-13 |
Glaxosmithkline Biologicals Sa |
RSV vaccination program
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
NZ616304A
(en)
|
2011-04-08 |
2016-01-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
HUE034673T2
(en)
|
2011-05-13 |
2018-02-28 |
Glaxosmithkline Biologicals Sa |
Pre-fusion rsv f antigens
|
ES2656050T3
(en)
|
2011-07-06 |
2018-02-22 |
Glaxosmithkline Biologicals Sa |
Immunogenic combination compositions and uses thereof
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
BR112014004162A2
(en)
|
2011-08-22 |
2018-04-24 |
Cangene Corp |
antibodies to clostridium difficile
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
PE20141547A1
(en)
|
2011-09-16 |
2014-10-25 |
Ucb Pharma Sa |
NEUTRALIZING ANTIBODIES AGAINST THE MAIN EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE
|
EP3311827B1
(en)
|
2011-10-03 |
2023-01-04 |
Canqura Oncology Ab |
Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
|
EP2765927B1
(en)
|
2011-10-12 |
2021-02-24 |
Vaxxas Pty Limited |
Delivery device
|
CA2854934A1
(en)
|
2011-11-07 |
2013-05-16 |
Novartis Ag |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
WO2013078299A1
(en)
*
|
2011-11-23 |
2013-05-30 |
Genocea Biosciences, Inc. |
Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
|
JP6121436B2
(en)
|
2011-11-23 |
2017-04-26 |
バイオベン・3・リミテッドBioven 3 Limited |
Recombinant proteins and their therapeutic uses
|
CA2857087C
(en)
|
2011-11-28 |
2021-05-25 |
Crucell Holland B.V. |
Influenza virus vaccines and uses thereof
|
WO2013082476A1
(en)
|
2011-11-30 |
2013-06-06 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
TR201908003T4
(en)
|
2012-02-07 |
2019-06-21 |
Infectious Disease Res Inst |
Advanced adjuvant formulations containing TLR4 agonists and their method of use.
|
DK2825640T3
(en)
|
2012-03-12 |
2016-08-01 |
Crucell Holland Bv |
BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
CA2867950C
(en)
|
2012-03-22 |
2023-02-21 |
Crucell Holland B.V. |
Vaccine against rsv
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
SI2850431T1
(en)
|
2012-05-16 |
2018-08-31 |
Immune Design Corp. |
Vaccines for hsv-2
|
ES2820898T3
(en)
|
2012-05-22 |
2021-04-22 |
Glaxosmithkline Biologicals Sa |
Meningococcal serogroup X conjugate
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
JP2015522580A
(en)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
Immunological compositions and uses thereof
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
JP2015525794A
(en)
|
2012-08-06 |
2015-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Method for eliciting an immune response against RSV and Bordetella pertussis in infants
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
WO2014043189A1
(en)
|
2012-09-14 |
2014-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes viruses and use thereof in vaccines
|
EP4056198A3
(en)
|
2012-09-18 |
2022-12-07 |
GlaxoSmithKline Biologicals SA |
Outer membrane vesicles
|
EP2903650B1
(en)
|
2012-10-02 |
2018-04-04 |
GlaxoSmithKline Biologicals SA |
Nonlinear saccharide conjugates
|
WO2014053612A1
(en)
|
2012-10-03 |
2014-04-10 |
Novartis Ag |
Immunogenic composition
|
PE20151720A1
(en)
|
2013-03-08 |
2015-12-10 |
Crucell Holland Bv |
ACELLULAR VACCINE AGAINST PERTUSSIS
|
MY187936A
(en)
|
2013-03-15 |
2021-10-29 |
In3Bio Ltd |
Self-assembling synthetic proteins
|
TW201502136A
(en)
|
2013-03-15 |
2015-01-16 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2014163558A1
(en)
|
2013-04-01 |
2014-10-09 |
Moreinx Ab |
Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
|
EA032326B1
(en)
|
2013-04-18 |
2019-05-31 |
Иммьюн Дизайн Корп. |
Gla monotherapy for use in cancer treatment
|
EA039803B1
(en)
|
2013-04-25 |
2022-03-15 |
Янссен Вэксинс Энд Превеншн Б.В. |
Stabilized soluble prefusion rsv f polypeptides
|
WO2014191435A1
(en)
|
2013-05-30 |
2014-12-04 |
Crucell Holland B.V. |
Influenza virus vaccines and uses thereof
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
CA2914792C
(en)
|
2013-06-17 |
2024-02-27 |
Crucell Holland B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
WO2015000832A1
(en)
|
2013-07-02 |
2015-01-08 |
Crucell Holland B.V. |
Method for preparing virosomes
|
WO2015000831A1
(en)
|
2013-07-02 |
2015-01-08 |
Crucell Holland B.V. |
Method for preparing virosomes
|
EP3492097A1
(en)
|
2013-08-05 |
2019-06-05 |
GlaxoSmithKline Biologicals S.A. |
Combination immunogenic compositions
|
WO2015063611A2
(en)
|
2013-11-01 |
2015-05-07 |
University Of Oslo |
Albumin variants and uses thereof
|
DK3069138T3
(en)
|
2013-11-15 |
2019-04-08 |
Univ Oslo Hf |
CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
BR112016015422A2
(en)
|
2013-12-31 |
2017-10-24 |
Infectious Disease Res Inst |
single vial vaccine formulations
|
NZ759686A
(en)
|
2014-01-21 |
2023-07-28 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
US20170065702A1
(en)
|
2014-02-19 |
2017-03-09 |
Cangene Corporation |
Methods of modulating an immune response
|
US20170224805A1
(en)
|
2014-02-20 |
2017-08-10 |
Vaxart, Inc. |
Formulations for small intestinal delivery
|
BR112016022011A2
(en)
|
2014-03-26 |
2017-10-24 |
Glaxosmithkline Biologicals Sa |
? mutant staphylococcal protein antigen, fusion protein, and immunogenic composition?
|
AU2015243246B2
(en)
|
2014-04-10 |
2018-09-06 |
Obi Pharma Inc. |
Antibodies, pharmaceutical compositions and uses thereof
|
MX2016016533A
(en)
|
2014-06-13 |
2017-05-01 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations.
|
TW201623329A
(en)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof
|
PE20170290A1
(en)
|
2014-07-10 |
2017-03-26 |
Janssen Vaccines And Prevention B V |
VACCINES AGAINST INFLUENZA VIRUSES AND USES OF THEM
|
WO2016011386A1
(en)
|
2014-07-18 |
2016-01-21 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
JP7158853B2
(en)
|
2014-10-10 |
2022-10-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
An immunogenic composition for treating food or respiratory allergies in a subject and for intranasal administration to said subject
|
AU2015341926B2
(en)
|
2014-11-04 |
2018-09-27 |
Janssen Vaccines & Prevention B.V. |
Therapeutic HPV16 vaccines
|
KR102149760B1
(en)
|
2015-01-15 |
2020-08-31 |
화이자 인코포레이티드 |
Immunogenic composition for use in pneumococcal vaccine
|
EP3253440B1
(en)
|
2015-02-02 |
2022-12-21 |
Vaxxas Pty Limited |
Microprojection array applicator
|
CA2977493C
(en)
|
2015-03-03 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
WO2016141320A2
(en)
|
2015-03-05 |
2016-09-09 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
AU2016249798B2
(en)
|
2015-04-14 |
2022-05-26 |
Janssen Vaccines And Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
JP2018521016A
(en)
|
2015-06-03 |
2018-08-02 |
アフィリス・アクチェンゲゼルシャフトAffiris Ag |
IL-23-p19 vaccine
|
AU2016274599B2
(en)
|
2015-06-12 |
2021-09-02 |
Vaxart, Inc. |
Formulations for small intestinal delivery of RSV and norovirus antigens
|
EP3319634B1
(en)
|
2015-07-07 |
2019-08-21 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
DK3319633T3
(en)
|
2015-07-07 |
2021-02-01 |
Janssen Vaccines & Prevention Bv |
VACCINE MOD RSV
|
CA2991544A1
(en)
|
2015-07-07 |
2017-01-12 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
TWI756893B
(en)
|
2015-07-21 |
2022-03-01 |
美商輝瑞股份有限公司 |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
AU2016309743B2
(en)
|
2015-08-20 |
2019-02-07 |
Janssen Vaccines & Prevention B.V. |
Therapeutic HPV18 vaccines
|
JP6975709B2
(en)
|
2015-09-02 |
2021-12-01 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
Stabilized virus class I fusion protein
|
SG10201913145SA
(en)
|
2015-09-03 |
2020-02-27 |
Novavax Inc |
Vaccine compositions having improved stability and immunogenicity
|
AR105910A1
(en)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
GLICAN MATRICES AND METHOD OF USE
|
CN116063481A
(en)
|
2015-09-04 |
2023-05-05 |
普里玛托普医疗股份有限公司 |
Humanized anti-CD 40 antibodies and uses thereof
|
EP3138579A1
(en)
|
2015-09-05 |
2017-03-08 |
Biomay Ag |
Fusion protein for use in the treatment of a hepatitis b virus infection
|
US11103259B2
(en)
|
2015-09-18 |
2021-08-31 |
Vaxxas Pty Limited |
Microprojection arrays with microprojections having large surface area profiles
|
US10786561B2
(en)
|
2015-11-20 |
2020-09-29 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
EP3393512A1
(en)
|
2015-12-23 |
2018-10-31 |
Pfizer Inc |
Rsv f protein mutants
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
TN2018000301A1
(en)
|
2016-03-14 |
2020-01-16 |
Univ Oslo |
Engineered immunoglobulins with altered fcrn binding
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
TWI780045B
(en)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
Antibodies, pharmaceutical compositions and methods
|
AU2017248021B2
(en)
|
2016-04-05 |
2021-08-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F proteins
|
AU2017248018A1
(en)
|
2016-04-05 |
2018-09-27 |
Janssen Vaccines & Prevention B.V. |
Vaccine against RSV
|
KR20230110820A
(en)
|
2016-04-22 |
2023-07-25 |
오비아이 파머 인코퍼레이티드 |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
CN109922829A
(en)
|
2016-05-02 |
2019-06-21 |
扬森疫苗与预防公司 |
Therapeutic HPV vaccine combination
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
MX2018014699A
(en)
|
2016-05-30 |
2019-02-28 |
Janssen Vaccines & Prevention Bv |
Stabilized pre-fusion rsv f proteins.
|
WO2017207477A1
(en)
|
2016-05-30 |
2017-12-07 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv f proteins
|
JP6683847B2
(en)
|
2016-06-20 |
2020-04-22 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
Strong and balanced bidirectional promoter
|
WO2017221072A2
(en)
|
2016-06-21 |
2017-12-28 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
EP3484506A1
(en)
|
2016-07-14 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Hpv vaccines
|
WO2018018082A1
(en)
|
2016-07-26 |
2018-02-01 |
The Australian National University |
Immunostimulatory compositions and uses therefor
|
CA3032049C
(en)
|
2016-07-27 |
2023-11-07 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
WO2018037045A1
(en)
|
2016-08-23 |
2018-03-01 |
Glaxosmithkline Biologicals Sa |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
EP3295956A1
(en)
|
2016-09-20 |
2018-03-21 |
Biomay Ag |
Polypeptide construct comprising fragments of allergens
|
US10350288B2
(en)
|
2016-09-28 |
2019-07-16 |
Genocea Biosciences, Inc. |
Methods and compositions for treating herpes
|
BE1024774B1
(en)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
COMPOSITIONS AND METHODS OF TREATMENT
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
EP3541414A4
(en)
|
2016-11-21 |
2020-11-11 |
OBI Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
MX2019006349A
(en)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof.
|
EP3570879B1
(en)
|
2017-01-20 |
2022-03-30 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
AU2018217935B2
(en)
|
2017-02-09 |
2020-04-30 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
US11123419B2
(en)
|
2017-03-15 |
2021-09-21 |
Novavax, Inc. |
Methods and compositions for inducing immune responses against Clostridium difficile
|
DK3606760T3
(en)
|
2017-03-31 |
2023-11-06 |
Vaxxas Pty Ltd |
ARRANGEMENT AND PROCEDURE FOR COATING SURFACES
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
AU2018267971A1
(en)
|
2017-05-17 |
2019-11-07 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
WO2018227246A1
(en)
|
2017-06-13 |
2018-12-20 |
Vaxxas Pty Limited |
Quality control of substrate coatings
|
IL300235A
(en)
|
2017-07-18 |
2023-03-01 |
In3Bio Ltd |
Synthetic proteins and therapeutic uses thereof
|
CN111148509A
(en)
|
2017-07-24 |
2020-05-12 |
诺瓦瓦克斯股份有限公司 |
Methods and compositions for treating respiratory disorders
|
EP3661587A4
(en)
|
2017-08-04 |
2021-06-09 |
Vaxxas Pty Limited |
Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (map)
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
EP3678699A1
(en)
|
2017-09-07 |
2020-07-15 |
University Of Oslo |
Vaccine molecules
|
US20200276299A1
(en)
|
2017-09-08 |
2020-09-03 |
Infectious Disease Research Institute |
Liposomal formulations comprising saponin and methods of use
|
WO2019053109A1
(en)
|
2017-09-15 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
Method for the safe induction of immunity against rsv
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
PT3743106T
(en)
|
2018-01-23 |
2022-08-24 |
Janssen Vaccines & Prevention Bv |
Influenza virus vaccines and uses thereof
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
MX2020009682A
(en)
*
|
2018-03-19 |
2020-10-12 |
Novavax Inc |
Multivalent influenza nanoparticle vaccines.
|
GB201807303D0
(en)
|
2018-05-03 |
2018-06-20 |
London School Of Hygeine & Tropical Medicine |
Glyconjugate vaccines
|
EP3569612A1
(en)
|
2018-05-18 |
2019-11-20 |
Biomay Ag |
Treatment and prevention of house dust mite allergies
|
WO2019224275A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
MX2020013553A
(en)
|
2018-06-12 |
2021-02-26 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides.
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
MX2021001479A
(en)
|
2018-08-07 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Processes and vaccines.
|
JP2021534761A
(en)
|
2018-08-23 |
2021-12-16 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Immunogenic proteins and compositions
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022513025A
(en)
|
2018-11-13 |
2022-02-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Stabilized pre-fusion RSVF protein
|
US20220016229A1
(en)
|
2018-12-12 |
2022-01-20 |
Pfizer Inc. |
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
TW202102256A
(en)
|
2019-03-05 |
2021-01-16 |
比利時商葛蘭素史密斯克藍生物品公司 |
Hepatitis b immunisation regimen and compositions
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
KR20220005002A
(en)
|
2019-04-25 |
2022-01-12 |
얀센 백신스 앤드 프리벤션 비.브이. |
Recombinant Influenza Antigen
|
MX2021013947A
(en)
|
2019-05-15 |
2021-12-14 |
Janssen Vaccines & Prevention Bv |
Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine.
|
JP2022532723A
(en)
|
2019-05-15 |
2022-07-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Co-administration of seasonal influenza vaccine and adenovirus-based respiratory syncytial virus vaccine
|
WO2020243115A1
(en)
|
2019-05-25 |
2020-12-03 |
Infectious Disease Research Institute |
Composition and method for spray drying an adjuvant vaccine emulsion
|
KR20220058527A
(en)
|
2019-06-25 |
2022-05-09 |
인3바이오 리미티드 |
Stabilized chimeric synthetic protein and its therapeutic use
|
AU2020318680A1
(en)
|
2019-07-21 |
2022-02-17 |
Glaxosmithkline Biologicals Sa |
Therapeutic viral vaccine
|
JP2022547107A
(en)
|
2019-09-05 |
2022-11-10 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Influenza virus vaccine and its use
|
WO2021084429A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2021097347A1
(en)
|
2019-11-15 |
2021-05-20 |
Infectious Disease Research Institute |
Rig-i agonist and adjuvant formulation for tumor treatment
|
US10953089B1
(en)
|
2020-01-27 |
2021-03-23 |
Novavax, Inc. |
Coronavirus vaccine formulations
|
TW202204380A
(en)
|
2020-01-31 |
2022-02-01 |
美商詹森藥物公司 |
Compositions and methods for preventing and treating coronavirus infection - sars-cov-2 vaccines
|
JP2023514697A
(en)
|
2020-02-23 |
2023-04-07 |
ファイザー・インク |
E. coli composition and method
|
WO2021229448A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Pharmaceuticals, Inc. |
Rna replicon encoding a stabilized corona virus spike protein
|
CA3183086A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
CN115884786A
(en)
|
2020-05-11 |
2023-03-31 |
杨森制药公司 |
SARS-CoV-2 vaccine
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
BR112022026408A2
(en)
|
2020-06-29 |
2023-01-17 |
Janssen Vaccines & Prevention Bv |
VACCINE COMBINATION AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION
|
BR112022026974A2
(en)
|
2020-07-06 |
2023-01-24 |
Janssen Pharmaceuticals Inc |
STABILIZED FUSION PROTEINS OF CORONAVIRUS PEAK PROTEINS
|
JP2022060169A
(en)
|
2020-10-02 |
2022-04-14 |
ファイザー・インク |
Cell culture process for rsv f protein production
|
KR20230096033A
(en)
|
2020-10-27 |
2023-06-29 |
화이자 인코포레이티드 |
Escherichia coli composition and method thereof
|
CN116744965A
(en)
|
2020-11-04 |
2023-09-12 |
辉瑞大药厂 |
Immunogenic compositions for pneumococcal vaccines
|
MX2023006320A
(en)
|
2020-12-02 |
2023-06-14 |
Glaxosmithkline Biologicals Sa |
Donor strand complemented fimh.
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
EP4032547A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Hsv1 fce derived fragements for the treatment of hsv
|
WO2022175479A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Vaccine combinations against respiratory syncytial virus strain a and b infections
|
KR20230147156A
(en)
|
2021-02-19 |
2023-10-20 |
얀센 백신스 앤드 프리벤션 비.브이. |
Stabilized pre-fusion RSV FB antigen
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
CN117320745A
(en)
|
2021-03-30 |
2023-12-29 |
维拉瓦克斯股份公司 |
SARS-COV-2 subunit vaccine
|
WO2022207793A1
(en)
|
2021-03-31 |
2022-10-06 |
Vib Vzw |
Vaccine compositions for trypanosomatids
|
WO2022207839A2
(en)
|
2021-04-01 |
2022-10-06 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
WO2023046898A1
(en)
|
2021-09-23 |
2023-03-30 |
Viravaxx AG |
Hbv vaccine inducing pres-specific neutralizing antibodies
|
WO2023047348A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized corona virus spike protein fusion proteins
|
WO2023047349A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
WO2023110618A1
(en)
|
2021-12-16 |
2023-06-22 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2023217988A1
(en)
|
2022-05-12 |
2023-11-16 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
WO2024017682A1
(en)
|
2022-07-18 |
2024-01-25 |
Janssen Vaccines & Prevention B.V. |
Rsv immunogens
|
US20240042021A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024061757A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Pre-fusion human piv1 f proteins
|
WO2024061759A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized coronavirus s proteins
|
WO2024061753A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized trimeric class i fusion proteins
|
WO2024074584A1
(en)
|
2022-10-06 |
2024-04-11 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|